Le Lézard
Classified in: Health
Subjects: CHI, SVY, HSP, ASI, BLK, DEI

An Unfair Fight: How Race and Social Determinants Impact Maternal and Infant Health


PLYMOUTH MEETING, Pa., June 17, 2021 /PRNewswire/ -- ProgenyHealth, LLC, a provider of comprehensive NICU care management for premature and medically complex newborns, today announced the release of a special industry report detailing how race and social determinants impact maternal and infant health.

Entitled "An Unfair Fight" ? the comprehensive report highlights how racism relates to maternal and infant mortality rates and provides insights into how health inequities are driven beyond factors of social determinants of health. The report also urges immediate social action for health providers, health plans and policy makers.

"Though long overdue, our country is finally acknowledging a national crisis. There is a mountain of data that shows Black, Asian American, Pacific Islander, Native American, Alaska Native, and Latinx individuals are disproportionately likely to experience adverse health problems. Nowhere is this more evident than in maternal and infant health," said Ellie Stang, MD, founder and CEO of ProgenyHealth.

"An Unfair Fight" is currently available for download here.

About ProgenyHealth
ProgenyHealth, LLC, is the only national company dedicated exclusively to NICU Care Management ? utilization management, case management and payment validation and assurance services. Our board certified neonatologists, pediatric intensivists, NICU/pediatric nurses, and social workers collaborate with providers on behalf of Medicaid and commercial health plans, as well as large employers, to ensure health care services follow evidence-based best practices and are medically necessary. In 2020 alone, we solved for more than 12,000 social determinants of health issues. ProgenyHealth's integrated program has proven effective in managing nearly 100,000 NICU cases, in over 1,400 hospitals, in all 50 states. We are measurably improving health outcomes for premature and medically complex newborns and delivering quantifiable cost savings to our partners. For more information, visit www.progenyhealth.com.

Media Contact:
Linda Smith
VP, Marketing & Communications
[email protected] 
Mobile: 609.206.1552

SOURCE ProgenyHealth


These press releases may also interest you

at 04:32
According to the latest BCC...

at 03:05
In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER). The dermatology portfolio saw accelerated growth in revenue of 16%. The acquisition of TMB-001 to the treatment of congenital ichthyosis added a late-stage...

at 02:22
Hansa Biopharma AB (publ), ("Hansa" or the "Company") (STO: HNSA) today announced that the company's registered share capital and number of shares and votes have increased through the issue of 10,474,740 new ordinary shares on 12 April 2024, whereby...

at 02:20
Vicore Pharma Holding (STO:VICO) Stockholm, May 3 2024- Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim...

2 mai 2024
The report titled "Muscle Stimulator Market by Technique (Burst Mode Alternating Current, Functional Electrical Stimulation, Interferential), Modality (Handheld, Portable, Table Top), Area, Application, End-User - Global Forecast 2024-2030" is now...

2 mai 2024
Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523), and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have...



News published on and distributed by: